BRAINWeek Conference 2024 | Digital Program Guide

MOBILE APP Search for: BRAINWEEK 2024

BRAINWEEKMEETINGWIFI

SSID: WK_CONFERENCE

PASSWORD: LILLY

Photography and Videography Disclaimer

By entering an event or program of the BRAINWeek 2024 Conference, you are entering an area where photography, audio and video recording may occur.

Your entry and presence on the event premises constitutes your consent to be photographed, lmed, and/or otherwise recorded and to the release, publication, exhibition, or reproduction of any and all recorded media of your appearance, voice, and name for any purpose whatsoever in perpetuity in connection with the BRAINWeek 2024 Conference and its initiatives, including, by way of example only, use on websites, in social media, news and advertising.

By entering the event premises, you waive and release any claims you may have related to the use of recorded media of you at the event, including, without limitation, any right to inspect or approve the photo, video or audio recording of you, any claims for invasion of privacy, violation of the right of publicity, defamation, and copyright infringement or for any fees for use of such record media.

You understand that all photography, lming and/or recording will be done in reliance on this consent. If you do not agree to the foregoing, please do not enter the event premises.

EXHIBIT HALL HOURS

THURSDAY, MAY 9

7:00 AM - 7:30 AM 9:30 AM - 10:00 AM 3:45 PM - 4:15 PM

NETWORKING RECEPTION 5:30 PM - 6:30 PM

FRIDAY, MAY 10 7:00 AM - 7:30 AM 9:30 AM - 10:00 AM 3:00 PM - 3:30 PM

ProgramGuideSponsor

ScilexPharmaceuticals Lilly

WIFISponsor

FACULTY

ALON AVIDAN, MD

DIRECTOR, UCLA SLEEP DISORDERS CENTER PROFESSOR, UCLA DEPARTMENT OF NEUROLOGY

DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA

Dr. Avidan is a Professor of Neurology at UCLA where he serves as Director of the UCLA Sleep Disorders Center. He completed his Neurology Residency at the Georgetown University Medical Center, and Fellowship in Sleep Medicine at the Cleveland Clinic. He was recently awarded and served as Visiting Professor of Neurology Education in the Department of Neurology at the Mayo Clinic College of Medicine in Rochester, Minnesota, and was selected to receive the 2014 American Academy of Sleep Medicine (AASM) Excellence in Education Award, for career contributions to education in sleep medicine.

He has published over 100 manuscripts on sleep disorders and had coauthored four books: “Handbook of Sleep Medicine,” “Geriatric Sleep Medicine,” “Review of Sleep Medicine” and Atlas of Clinical Sleep Medicine.” He is a Diplomate of the American Board of Psychiatry and Neurology, the American Board of Sleep Medicine, and a Diplomate in the Specialty of Sleep Medicine by the American Board of Psychiatry and Neurology. He is a Fellow of the American Academy of Neurology and the American Academy of Sleep Medicine.

DANI CABRAL, MD

NEUROLOGIST/PSYCHIATRIST

UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE

Dr. Dani Cabral is a double board-certi ed neurologist and psychiatrist and Alzheimer’s/dementia subspecialist with expertise in clinical care and clinical trials. She received her medical degree from the University of Arizona College of Medicine- Phoenix and completed residency and fellowship at Brown University in Rhode Island. She works as a Principal Investigator for IMA Clinical Research in Phoenix where she leads clinical trials in dementia, psychiatric illness, and cardiovascular disease. Dr. Cabral provides frequent professional and community education on Alzheimer’s disease and related dementias with the goals of elevating the understanding of the rapid advances in diagnosis and treatment to help clinicians, patients, families, and communities.

ANN

CHILDRESS, MD PRESIDENT CENTER

FOR PSYCHIATRY AND BEHAVIORAL MEDICINE, INC.

Dr. Childress is president of the Center for Psychiatry and Behavioral Medicine, Inc. where about 80% of her practice is research based. She also has adjunct faculty appointments at the University of Nevada Las Vegas School of Medicine and Touro University of Nevada College of Medicine. She is board certi ed in psychiatry, with a subspecialty in child and adolescent psychiatry.

Before earning her medical degree at the Medical University of South Carolina, Charleston, Dr. Childress studied at St. Louis University School of Medicine, St. Louis, Missouri. She completed a psychiatry internship and residency and a fellowship in child and adolescent psychiatry at the Medical University of South Carolina.

Dr. Childress has authored more than 80 articles in scienti c journals and a book chapter. As a co-principal investigator, she has participated in more than 180 clinical trials. Her research has focused on treatment of children and adolescents with mood disorders, post-traumatic stress disorder, schizophrenia, autism and Attention-De cit / Hyperactivity Disorder .

Dr. Childress is President-elect of the American Professional Society of ADHD and Related Disorders, Education Director for the Nevada Psychiatric Association, a distinguished fellow of the American Psychiatric Association and a member of the American Academy of Child and Adolescent Psychiatry.

Dr. Childress is an internationally recognized expert in the treatment of ADHD.

WADE COOPER, DO NEUROLOGIST

MEMORIAL HEALTHCARE

Dr. Cooper earned his medical degree from Michigan State University College of Osteopathic Medicine. He completed a neurology residency at Michigan State University and is board-certi ed in Neurology and Psychiatry. Dr. Cooper obtained a fellowship in Headache Medicine from the Michigan Head Pain and Neurological Institute in Ann Arbor.

Prior to joining Memorial Healthcare Institute for Neuroscience, Dr. Cooper was a Director at the Headache & Neuropathic Pain Clinic and Program Director of the Headache Medicine Fellowship Training Program at the University of Michigan, Ann Arbor. He is a Fellow for the American Headache Society and serves on several neurological boards and committees. Dr. Cooper has co-authored numerous journal articles and book chapters and has served as a reviewer for various journals. He routinely presents regionally and at national conferences.

DA'MOND GADSON, DBH, LPC, MPC, MED PSYCHOLOGICAL THERAPIST

ABRA HEALTH

Dr. Da’mond Gadson is a Bilingual “Spanish and English” African American/Black Psychological Therapist with a Doctorate in Behavioral Health from Arizona State University. He works with clients of all ages, backgrounds, and behavioral needs. He possesses an in-depth understanding of psychological disorders, treatment techniques, diagnosis, and interventions. This includes assessing and psychological testing with disciplinary teams in Primary Care, Integrated Care, and mental health settings. He solves problems by using the client’s strengths to combat challenges. He integrates the role of the mind, body, and spirit in therapy.

MARK GAROFOLI, PHARMD, MBA, BCGP, CPE

CLINICAL ASSISTANT PROFESSOR & CLINICAL PAIN/ADDICTION PHARMACIST WEST VIRGINIA UNIVERSITY & WEST VIRGINIA UNIVERSITY MEDICINE

Mark Garofoli is a Pitt PharmD graduate, Strayer MBA graduate, Board-Certi ed Geriatric Pharmacist (BCGP), Certi ed Pain Educator (CPE), and Certi ed Tobacco Treatment Specialist (CTTS). His past positions include being a pharmacist leader with CVS Health, Humana, and the WV Safe & E ective Management of Pain (SEMP) Program, along with coordinating the WV SEMP Guidelines Panel. Today, he is WVU School of Pharmacy faculty, WVU School of Pharmacy Director of Experiential Learning, WVU School of Medicine Pain Fellowship Faculty, and a WVU Medicine Pain & Addiction Pharmacist. Mark “Pain Guy” Garofoli has been a 2021 TEDx Talker, CDC grant reviewer, civil/criminal expert witness, seasoned CE developer and presenter, host of the Pain Pod (Pharmacy Podcast Network), Editor of the Pain Press, and publishes the www.painguy.us website.

NATALIE GOLDBERG, LPN

NURSE AUTHOR

PSYCHEDELIC SUPPORT

Natalie Goldberg, an accomplished writer and practitioner within the realm of healthcare and psychedelics, brings a nuanced perspective through a background in ne arts and psychiatric nursing. As a dedicated contributor to a leading psychedelic company, her unique articles, including ‘From Panic to Perspective: A Nurse’s Journey Through a Challenging ‘Psychedelic Trip,’ explore the combination of mental health and alternative therapies. Emphasizing a compassionate approach, Natalie navigates the complexities of healthcare by bringing together traditional practices with the evolving possibilities of psychedelics.

FACULTY

SHANA JOHNSON, MD

PHYSICAL MEDICINE & REHABILITATION

KONDITION PLLC

Shana Johnson is a board-certi ed physician in physical medicine and rehabilitation. She is a regular contributor to WebMD, Psychology Today, and medical news. She is the author of Sunbreak: Healing the Pain No One Can Explain, which shines a light on the stress-illness connection with central sensitization syndromes.

Her work experience includes being co-director of the UW Medicine Multiple Sclerosis Center and medical director at the WA state Medicaid program, where she developed evidence-based medical policy. Currently, she is the owner of AskDrShana Physical Medicine and Rehabilitation, which provides pain management programs combining Western and Eastern philosophies of treatment.

KRISTEN LEE, ED.D., LICSW LEAD FACULTY FOR BEHAVIORAL SCIENCE AND FACULTY-IN-RESIDENCE NORTHEASTERN UNIVERSITY

Dr. Kristen Lee, Ed.D., LICSW, known as “Dr. Kris”, is an internationally recognized, award-winning behavioral science clinician, researcher, educator, speaker, comedian, and from Boston, Massachusetts. As the Lead Faculty for Behavioral Science and Faculty-in-Residence at Northeastern University, Dr. Kris’s research and teaching interests include individual and organizational well-being and resilience, particularly for marginalized and underserved populations. Dr. Kris works with organizations and leaders around the world on how to use the science of behavioral change and human potential to build healthy mental health cultures that help prevent burnout and promote organizational and human sustainability.

Dr. Kris is the author of RESET: Make the Most of Your Stress, Winner of the Next Generation Indie Book Awards Motivational Book of 2015; best-selling Mentalligence: A New Psychology of Thinking-Learn What it Takes to be More Agile, Mindful and Connected in Today’s World, and Worth the Risk: How to Microdose Bravery to Grow Resilience, Connect More, and O er Yourself to the World, a 2022 The Next Big Idea Book Club nominee and Nautilus Book Award Silver Medal Winner. She is a regular contributor for Psychology Today and Thrive Global. Dr. Kris’s work has been featured on NPR, Ted, Forbes Fast Company, and CBS radio.

She is the host of Crackin’ Up: Where Therapy Meets Comedy. Dr. Kris’s work has been featured on NPR, Ted, and CBS radio. Her Ted X talk, The Risk You Must Take has over 427K views. In 2022, she received a First Place MVP award from EdTech for her work with Pathify and Active Minds on addressing mental health challenges in higher education Her signature ability to engage with a diverse range of audiences has led her to be invited to speak nationally and internationally to students, educators, health and mental health professionals, business leaders and general audiences. Some of the venues she speaks at include Harvard University, Harvard Medical School, Nationwide, Snapchat, American Chemical Society, Virgin Pulse, and Johnson and Johnson.

Dr. Kris is a Licensed Independent Clinical Social Worker known for her advocacy in promoting increased mental health integration in social policies and institutions to facilitate access and improved health outcomes in the U.S. and across the globe. She has served at as a U.S. federal grant reviewer for the Departments of Minority A airs, Substance Abuse and Mental Health Administration, and Health and Human Services. She is a member of the National Association of Social Workers and the American Psychological Association. She holds a BS from Worcester State University, MSW from Boston University and an Ed.D. from Northeastern University. In 2011, Dr. Kris was the recipient of an Excellence in Teaching Award from Northeastern University for her “depth of knowledge” and “engaging teaching style”. In 2023, she was honored an honorary doctorate and in 2015, she was honored with the Distinguished Professional Achievement Award from Worcester State University as “a leader who lives by the highest intellectual and ethical standards”. To learn more, visit www.kristenlee.com or connect on social media via @TheRealDrKris."

THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC

ADULT NURSE PRACTITIONER

STANFORD HEALTH CARE - DIVISION PAIN MEDICINE

Theresa is an Adult Nurse Practitioner with over 27 years’ experience at Stanford Health Care in Palo Alto, California. She received her graduate degree from University of California, San Francisco.

Theresa’s current clinical practice within the Division of Pain Medicine, focuses primarily on evaluation and treatment of individuals su ering from acute and chronic pain conditions in both the hospital and outpatient settings. Her subspecialty within the Division of Pain Medicine is diagnosis and management of chronic headache. She also has an interest in pain in pregnancy and recently published a book, “Holistic Pain Management in Pregnancy”.

As part of her commitment to education and professional development, she lectures extensively on topics surrounding pain management both locally and regionally. She has authored and co-authored numerous articles, abstracts, and book chapters on topics pertaining to pain assessment and management. As part of her commitment to safety and ethical treatment of patients with pain; Theresa has provided services as an independent expert witness on issues related to pain management and treatment.

Theresa is currently involved in multidisciplinary research and education projects at Stanford University and Medical Center involving compassionate opioid weaning through the EMPOWER study, as well as providing guided motivational counseling to patients recovering from surgery, as part of the PROMPT trial. Theresa is actively involved in multiple professional organizations including: The American Association of Nurse Practitioners, California Association of Nurse Practitioners and American Academy of Pain Medicine. She is on the editorial advisory board of Practical Pain Management and contributes a quarterly article for the Advanced Practice Provider. Theresa is the past co-chair of the pain management special practice group at AANP, as well as the current co-chair of the APRN/PA special interest group at AAPM.

Amongst her numerous honors, the two that stand out as the most treasured were awarded by peer nomination, Nurse Practitioner of the Year (Pain Medicine) – Point of Care Network in 2019 & 2021 & 2022, and Advanced Practice Provider of the Year – Stanford Health Care in 2015.

PAUL MATHEW, MD, DNBPAS, FAAN, FAHS

ASSISTANT PROFESSOR OF NEUROLOGY

HARVARD MEDICAL SCHOOL/MASS GENERAL BRIGHAM/ATRIUS HEALTH

Paul G. Mathew, MD, DNBPAS, FAAN, FAHS completed his neurology residency at Temple University Hospital, Philadelphia, PA and a fellowship in headache medicine at Mayo Clinic, Rochester, MN. He is an Assistant Professor of Neurology at Harvard Medical School (HMS), and an A liate Member of the HMS Division of Sleep Medicine. He has clinical appointments at Mass General Brigham and Atrius Health. In addition, he serves as the Chair of the American Headache Society’s Trigeminal Autonomic Cephalgia Section, on the advisory board of the National Board of Physicians and Surgeons, and as Co-Chief Medical Editor of the journal Practical Neurology.

PROGRAM | THURSDAY, MAY 9

7:00AM-7:30AM

7:30AM-8:30AM

HIGHER EDUCATION: A REVIEW OF CANNABIS AND CANNABINOIDS

Mark Garofoli, PharmD, MBA, BCGP, CPE

BRW-01

8:30 AM – 9:30 AM

Kierland Ballroom 3

"Medical" Marijuana, Recreational Marijuana, Weed, Hemp, Cannabis, Cannabinoids, CBD, THC, when will the madness end, or begin? Cannabis has been around for centuries, and debates continue as to its usefulness and legality. Almost every U.S. state has had a legal shi in regards to Cannabis in some form or fashion. Bring any “budding” questions as we provide a “higher education” of clinically practical knowledge, with a dash of entertainment, for all things Cannabis. It's time to dive deeper into the weeds.Attendees will be able to understand and explain the pharmacological properties of Cannabis and Cannabinoids that contribute to polarized, sensationalized, and generally misunderstood conversations across our country. A comprehensive, yet succinct, discussion of the Cannabis and Cannabinoids including dynamic patient care principles.

THE ELEPHANT IN THE ROOM: DISCUSSING THE ROLE OF THE ENDOCANNABINOID SYSTEM ON WELLNESS AND DISEASE

Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

BRW-02

Kierland Ballroom 3

The endocannabinoid system has a regulatory role in both the central nervous system (CNS) and peripheral processes. It also has been shown to have immunoregulatory properties. A basic understanding of the functioning and regulation of endocannabinoid system, will provide the clinician in neurosciences and mental/behavioral health with a greater appreciation for the role of this homeostatic regulatory system on anxiety, depression, neurogenesis, neurological health, reward, cognition, learning, and memory.Currently, there are NO states in the U.S. that DO NOT have legalization for either medicinal or recreational cannabis use, including the federal legality of CBD from hemp with less than 0.3% THC. This session will provide basic, non-biased, concise and useful information to Clinicians that is vital to guide the safe treatment and counseling of their patients. In addition, an understanding and appreciation for the role of the endocannabinoid system, in maintaining neurological stability and the role it plays in chronic neurological disease will allow the audience to destigmatize the medicinal use of cannabis in their patients.

9:30AM-10:00AM EXHIBITOR BREAK

10:00 AM – 11:00 AM

Kierland Ballroom 2

FOSTERING THE ACCURATE RECOGNITION, EVALUATION, AND DIAGNOSIS OF ADHD IN DIVERSE PATIENT POPULATIONS

Ann Childress, MD

BRW-03

11:00 AM – 12:00 PM

Kierland Ballroom 3

According to a 2016 survey, nearly 23% of children with ADHD were receiving neither medication treatment nor behavior treatment for their condition. ADHD is also more likely to go undiagnosed and undertreated in women and girls than in males due to di erences in symptom presentation. Unfortunately, these gaps in diagnosis and treatment can have an adverse impact on academic performance and overall prognosis. Join us for this timely and engaging session led by world-renowned expert in ADHD, Dr. Ann Childress, as she discusses the current state of disparities in ADHD diagnosis and treatment and elucidates the diagnostic and evaluative pathways for ADHD in diverse patient populations, as well as the implications for overall health. This dynamic and insightful session will provide education and clinical strategies that are imperative for every clinician’s toolbox as they look to advance and optimize patient outcomes. You don’t want to miss it!

“DOCTOR,

I CANNOT SLEEP, PLEASE HELP!” CHRONIC INSOMNIA DISORDER: MECHANISM, EVALUATION, AND MULTIDISCIPLINARY MANAGEMENT

Alon Avidan, MD

BRW-04

Kierland Ballroom 3

Let’s take a walk-through dreamland! In this course, our expert faculty speaker will lead us on an explorative journey through the implications of insomnia, and comorbid primary sleep, medical and psychiatric disorders on overall health. Learners will be given tools to help uncover treatment and management strategies to help optimize patient care. Sleep de ciency is linked to multiple chronic health issues, including heart disease, kidney disease, high blood pressure, diabetes, stroke, obesity, and depression. It is also associated with a higher risk of accidents and injury, including serious car crashes, plane crashes, broken bones, and falls. This BRAINWeek session will provide both frontline clinicians and specialists with expert and comprehensive insights into how to accurately recognize signs of chronic insomnia disorder in clinical practice and will help learners apply appropriate care strategies to enhance patient outcomes and overall well-being. This session will also discuss the complexities of comorbid psychiatric conditions, their bidirectionality with sleep disturbances and their adverse impact on health.

12:05 PM – 1:35 PM LUNCH ON YOUR OWN

1:40 PM – 2:40 PM

UPDATES

ON THE CURRENT TREATMENT ARMAMENTARIUM FOR ADHD

Ann Childress, MD

BRW-05

2:40 PM – 3:40 PM

Kierland Ballroom 3

A variety of therapeutic modalities are available to optimize the treatment and management of patients with ADHD, including pharmacological and non-pharmacological options. However, controversy surrounding possible overtreatment, medication misuse, and pharmacological undertreatment have all been noted as issues in ADHD care. In this stimulating and highly informative discussion with world-renowned expert Dr. Ann Childress, both the pharmacological and non-pharmacological treatment armamentarium for ADHD will be explored, including practical clinical strategies for selecting and individualizing therapies in adult and pediatric populations and how to best address treatment challenges to ensure optimal patient outcomes.

HEADACHE: IT'S ALL IN YOUR HEAD…OR IS IT?

Paul Mathew, MD, DNBPAS, FAAN, FAHS

BRW-06

Kierland Ballroom 3

Headache is one of the most common complaints among patients presenting to an outpatient primary care, neurology, or pain practice. The evaluation, diagnosis, and treatment of headache can be rather cumbersome, and at times quite challenging for even the most seasoned clinician. Many complex issues that although not causative, can play a triggering role in the genesis of headaches. This presentation will review some of the essential elements that are part of headache evaluation including headache-speci c history, physical examination, warning signs of secondary headache disorders, and when to consider additional studies.

3:45 PM – 4:15 PM EXHIBITOR BREAK

4:20 PM – 5:20 PM

Kierland Ballroom 2

KEYNOTE: MORE THAN MEETS THE EYE: EXPLORING THE DISCOVERY OF NEWER CLASS TREATMENTS FOR MIGRAINE AND THEIR LINK TO THE GUT-BRAIN AXIS AND AUTONOMIC CONTROL

Wade Cooper, DO Kierland Ballroom 3

KEY-01

The current treatment landscape for migraine has seen an emergence of new and more e ective pharmacological and non-pharmacological therapeutic options, particularly for patients with refractory and more challenging migraine presentations. In addition, advancements in research have opened doors to other useful discoveries regarding the link between migraine and the gut-brain axis and autonomic control. This pivotal and dynamic keynote session will help clinicians optimize care in patients with migraine by outlining the e ectiveness and applicability of new treatment options, and by examining novel research discoveries that have the propensity to alter the course of migraine treatment and management.

5:30 PM – 6:30 PM WELCOME RECEPTION SPONSORED BY LILLY

Kierland Ballroom 2

PROGRAM | FRIDAY, MAY 10

7:00AM-7:30AM

7:30AM-8:30AM

8:30 AM – 9:30 AM

TAKING CENTER STAGE: THE ROLE OF CENTRAL SENSITIZATION SYNDROME IN MIGRAINE PROGRESSION AND CHRONIFICATION

Shana Johnson, MD

BRW-07

Ballroom 3

Central sensitization syndromes (CSS) a ect upwards of 30 million adults in the United States and the role of sensitization in migraine is not yet widely understood outside of chronic pain and neurology clinics.The presentation will focus on the diagnosis and management of migraines with sensitization and provide real-world examples and evidence-based research to enhance the providers' clinical knowledge and skills to be able to identify when sensitization is present and allow them to tailor the treatment plan accordingly. Educating patients on sensitization reduces overutilization of healthcare resources as patients understand how sensitization a ects their symptoms and are less prone to catastrophic thinking that a new or worsening illness is occurring with symptoms ares they are better able to self-manage.

WHAT DOES YOUR GUT TELL YOU? THE AFFECT OF THE GUT MICROBIOME ON NEUROLOGICAL DISORDERS

Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

BRW-08

Ballroom 3

The gut and brain connect via a neuro-immuno-humoral network of signaling pathways known as the gut–brain axis, which includes the vagus nerve, the immune system, the hormonal system. Disturbances of microbiota homeostasis and dysregulation of these pathways can cause pathological malfunctions, including neurological disorders. Increasing preclinical and clinical studies/evidence indicate that gut microbes are a possible susceptibility factor for the progression of neurological disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) and autism spectrum disorder (ASD).This session will examine what is known in the literature and where the research is heading in the examination of the connection between the gut microbiota and the central nervous system. Practical recommendations that clinicians can make to their patients to aid in the prevention and treatment of gut microbiota-related neurological disorders will be addressed.

TO CLAIM YOUR CREDIT FOR BRAINWEEK 2024, PLEASE VISIT AKHINC.FORMSTACK.COM/FORMS/240015

THE DEADLINE TO CLAIM CREDIT WILL BE JUNE 14TH

FOR ANY QUESTIONS REGARDING CREDIT CLAIM OR EVENT ACCREDITATION, PLEASE REACH OUT TO TBRIGNONI@AKHCME.COM

9:30AM-10:00AM EXHIBITOR BREAK Kierland Ballroom 2

10:00 AM – 11:00 AM

NEW HORIZONS IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS: UPDATES IN CLINICAL EVALUATION AND BIOMARKER TESTING

Dani Cabral, MD Kierland Ballroom 3

BRW-09

Did you know that half of individuals with Alzheimer’s disease (AD) and other dementias are never diagnosed, and for those who receive a diagnosis, the dementia is typically in the moderate to severe stages? The early recognition and accurate diagnosis of AD is critical to preserve patient functioning, ensure access to available treatments and interventions, build appropriate care teams, and provide adequate patient and caregiver support services. This cutting-edge session led by expert faculty will discuss groundbreaking updates in the clinical evaluation and diagnostic landscape of AD. This is essential as more e ective Alzheimer’s treatments are available. Learners will engage in the most current and immersive content regarding updated testing tools/methods to help accurately diagnose AD in practice, as well as evaluate, and interpret diagnostic ndings.

11:00 AM – 12:00 PM

HYPERSOMNIA AND NARCOLEPSY: RECOGNIZING SYMPTOMS, APPRECIATING DIFFERENTIAL DIAGNOSIS, AND REVIEWING 21ST CENTURY MANAGEMENT OPTIONS

Alon Avidan, MD

BRW-10

Kierland Ballroom 3

In this stimulating and expert-led session, we’re bringing the frontlines of sleep management and treatment to you! Although nearly 50 to 70 million Americans su er from chronic, or ongoing, sleep disorders. Severe sleepiness is common in clinical psychiatric and neurological care, but it is o en overlooked in practice, which when le unchecked, can have dire consequences for patient health and worsen depression. Join our expert faculty speaker for a vigorous examination of central disorders of hypersomnolence including narcolepsy. The discussion will provide an overview of symptom recognition and an opportunity to survey current data to improve early diagnosis of these disorders in clinical practice, understand the bidirectional relationship between these conditions and psychiatric health, and appraise current management guidelines and strategies to improve the care of people with narcolepsy and hypersomnolence.

12:00 PM – 1:00 PM LUNCH ON YOUR OWN

1:00 PM – 2:00 PM

THE NEW WORLD OF ALZHEIMER'S DISEASE: REAL, HYPE, OR BOTH?

Dani Cabral, MD

BRW-11

2:00 PM – 3:00 PM

In 2023, there were 6.5 million Americans with dementia, most of whom have Alzheimer’s disease as the cause. This presentation will highlight recent scienti c advances in Alzheimer’s disease diagnosis/treatment and translate them into real-world clinical practice highlighting what we know and the remaining gaps. The progress on Alzheimer's is exciting but remains controversial infused with important questions about the clinical meaningfulness of the treatments given potential serious side e ects and high nancial costs along with practical challenges for patients, families, healthcare providers, and payors.The course will enhance critical thinking skills, clinical knowledge and skills by: 1.) Enhancing understanding of the role of biomarkers in Alzheimer’s diagnosis providing practical guidance on current clinical use and reimbursement2.) Explaining clinical trial data for FDA-approved Alzheimer’s treatment including lack of diversity in study subjects, applicability to clinical practice, and discussion of systems needed for safe prescribing and monitoring.

HOW TRAUMA LEADS TO DRAMA: WHEN TO COLLABORATE WITH MENTAL HEALTH PROFESSIONALS FOR BETTER OUTCOMES

BRW-12

Ballroom 3

Da'mond Gadson, DBH, LPC, MPC, MED Kierland Ballroom 3

Research regarding the interaction between physical and mental health integration has recently gained momentum due to the increasing demand for healthcare providers to identify and provide impactful care during patient interactions. Unfortunately, the growing levels of daily trauma have made a signi cant impact on the e ectiveness of treating patients with physical health needs.This session will discuss how trauma and mental health mobilize in physical health environments and how a mental health provider may support your practice’s integrated care needs. Content will also include reviewing assessment tools to use when trauma or a mental health need is suspected and how to work collaboratively with mental health professionals o -site for patient retention.

3:00 PM – 3:30 PM EXHIBITOR BREAK Kierland Ballroom 2

3:30 PM – 4:30 PM

PHYSICIAN BURNOUT: DIAGNOSIS AND TREATMENT WITHOUT SUGARCOATING

Paul Mathew, MD, DNBPAS, FAAN, FAHS Kierland Ballroom 3

BRW-13

Clinician Burnout is highly prevalent, a ecting over 50% of clinicians in some studies. With such a phenomenon a ecting so many clinicians, there can be systemwide impacts. Burnout can result in clinicians reducing their hours, changing jobs, or even leaving healthcare to seek employment in other elds, which reduces access and continuity of care. Burnout can also result in reductions in care quality and patient safety.In this lecture, strategies for both the individual and institution to address clinician burnout will be discussed. With practical and implementable strategies, clinician burnout can be mitigated and potentially prevented.

4:30 PM – 5:30 PM

KEYNOTE: HOW TO LEVERAGE BEHAVIORAL SCIENCE TO OPTIMIZE WELL-BEING

Kristen Lee, Ed.D., LICSW

KEY-02

Within today’s “Age of Anxiety” and global mental health crisis, we need tangible ways to protect against burnout and optimize outcomes. This keynote teaches evidence-based habits, mindsets, and practices to help cope with and endeavor change. The science of human ourishing and behavioral change o ers a host of proven ways we can progress towards better individual and collective outcomes. This keynote provides a “double dip” toolbox of interactive, practical, evidence-based strategies to cultivate resilience and optimize well-being within the care continuum.

**This session is not certified for credit.**

3

PROGRAM | SATURDAY, MAY 11

7:00AM-7:30AM COFFEE/LIGHT BREAKFAST

7:30AM-8:30AM

LET'S GET PSYCHED: A REVIEW OF PSYCHEDELICS

Mark Garofoli, PharmD, MBA, BCGP, CPE

BRW-14

8:30 AM – 9:30 AM

Ballroom 2

Kierland Ballroom 3

Where to begin an understanding? The pharmacology, history, and policy of course. This session will dynamically review the foundational pharmacology of hallucinogens and discuss a brief history and policy respectively. All culminating with clinical pearls to directly improve patient care for attendees immediately.

A NURSE'S PATH: BLENDING PERSONAL EXPERIENCE AND PROFESSIONAL INSIGHT IN PSILOCYBIN TRAUMA THERAPY

Natalie Goldberg, LPN

BRW-15

Kierland Ballroom 3

This session will examine the use of psychedelics, with a focus on psilocybin, in the treatment of psychological trauma and post-traumatic stress disorders (PTSD). Providing perspective through a unique lens, an account of a nurse’s personal health journey involving treatment with psychedelics will be explored, merging both personal and clinical knowledge and experiences. This multimodal presentation will synthesize current research ndings and personal insights to provide clinicians with knowledge regarding the e cacy of psychedelics in trauma therapy, including bene ts and risks, and the role of shared decision-making and multidisciplinary care in optimizing patient outcomes.

9:30AM-9:45AM REFRESH BREAK

9:45 AM – 10:45 AM

LET'S TAKE A "TRIP": EXPLORING CASE STUDIES USING PSYCHEDELICS AS A TREATMENT OPTION

Mark Garofoli, PharmD, MBA, BCGP, CPE

BRW-16

Kierland Ballroom 3

Given the chaotic overlapping landscape of illicit substances, prescription medications, over-the-counter medications, and supplements, it’s easy for clinicians to get lost in the “delirium” when it comes to knowing which substances, including formulations and dosages, are FDA-approved for patient care, under clinical study, not approved for patient use, or outright illegal on a federal or state level.Alas, this session will aim to review FDA-approved psychedelic medications, research studies, and case studies in an e ort to clear the “haze” on what psychedelic medications clinicians can actually consider when providing patient care. Let’s take a trip, to optimized patient care!

11:00 AM ADJOURN

Scottsdale, AZ

May 9-11, 2024

Activity Overview

As a HCP, you’ll benefit from actionable, current information such as the latest research, treatment information, best practices, and other insights into neurological illness and mental illness. You’ll increase your knowledge about how to better assess, diagnose, and appropriately refer patients with brain health concerns. BRAINWeek’s expert faculty will delve into clinical and behavioral discussions surrounding some of the most frequent and pressing challenges HCPs face in their practices today. Courses may include integrative approaches to knowledge, for example, the relationship between nutrition and depression; exercise on the progression of Alzheimer’s; and use of the emerging treatment psilocybin (mushrooms) for mental health conditions, to name a few. You’ll also hear nationally known keynotes speakers, attend networking events, and have time to connect with colleagues.

Target Audience

This activity is designed for an audience of physicians, nurses, nurse practitioners, physician assistants, pharmacists, psychologists, and other healthcare professionals.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Recognize characteristics of neurocognitive disorders in clinical practice and select appropriate assessment tools for screening and evaluation.

Discuss recent FDA approved treatments for Alzheimer's disease, including mechanisms of action, applicability to clinical practice, safe prescribing and monitoring, the generalizability of treatments to diverse populations, and costs.

Recognize common sleep disorders in clinical practice and select appropriate treatments and management strategies to optimize patient outcomes.

Select standard assessment tools to evaluate psychiatric disorders in clinical settings.

Select appropriate treatment regimens and integrated care strategies for patients experiencing psychiatric conditions including depression, anxiety, attention deficit hyperactivity disorder (ADHD), and trauma.

Describe disparities in the diagnosis and treatment of various brain and mental health conditions and the impact on patient outcomes.

Evaluate and diagnose headache disorders and formulate comprehensive treatment strategies that consider pharmacological and non-pharmacological approaches.

Discuss the mechanisms of action, safety, and effects of various complementary and alternative therapies on brain and mental health conditions, including legal implications concerning their use.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form at https://akhinc.formstack.com/forms/240015. If you have questions about this CE activity, please contact AKH Inc at tbrignoni@akhcme.com.

Physicians

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and BRAINWeek. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 17 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses

Credit being awarded: 17 ANCC contact hours

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 17 contact hours.

Physician Assistant

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 17 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and BRAINWeek. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 17 contact hour(s) (which includes 2.25 hour(s) of pharmacology).

Psychologists

Commercial Support

This activity is supporte

DISCLOSURES

Name

Alon Avidan, MD

Dani Cabral, MD

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Consultant

Speakers Bureau

N/A

Merck, Takeda, Avadel, Idorsia

Idorsia, Avadel

Nothing to disclose Ann Childress, MD

Advisor

Consultant

Independent contractor (including contracted research)

Researcher

Wade Cooper, DO

Consultant

Ownership interest

Speaker

Da'mond Gadson, DBH, LPC, MPC, MED N/A

Mark Garofoli, PharmD, MBA, BCGP, CPE N/A

Natalie Goldberg, LPN N/A

Shana Johnson, MD N/A

Theresa Mallick-Searle, MS, PMGT-BC, ANP-BC N/A

Paul Mathew, MD, DNBPAS, FAAN, FAHS Consultant

Amy McLean, RN, ANP-BC/BSN, MSN, DNP N/A

Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

Speaker

Corium, Noven, Otsuka, Supernus

Aardvark, Aytu, Cingulate, Corium, Kempharm, Lumos, Medison, Neurocentria, Otsuka, Sky, Tulex

Aardvark, Acadia, Adlon, Akili, Axsome, Cingulate, Corium, Emalex, Lumos, Servier, Neurocentria, Otsuka, Purdue, Sunovion, Supernus, Takeda

Aardvark, Acadia, Adlon, Akili, Axsome, Cingulate, Corium, Emalex, Lumos, Servier, Neurocentria, Otsuka, Purdue, Sunovion, Supernus, Takeda

AbbVie, Eli Lilly, Lundbeck, Pfizer, Tonix, Dolor Technologies

Dolor Technologies

AbbVie, Lundbeck

Nothing to disclose

Nothing to disclose

Nothing to disclose

Nothing to disclose

Nothing to disclose

Amgen, AbbVie, Pfizer, Lilly, Upsher-Smith, Impel, Tonix, Theranica, Linical

Nothing to disclose

AbbVie

Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations N/A

Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) N/A

Dorothy Duffy, RPh (planner/reviewer) N/A

Donna Teresa Purcell, Psy.D. (planner/reviewer) N/A

Michele Bielarski, RN (planner/reviewer) N/A

AKH Inc Staff and Planners N/A

Nothing to disclose

Nothing to disclose

Nothing to disclose

Nothing to disclose

Nothing to disclose

Nothing to disclose BRAINWeek Staff and Planners N/A

Disclosures

Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.

NON EDUCATIONAL CONTENT

THANK YOU TO OUR EVENT SPONSORS

FLOOR PLAN

EXHIBIT HALL

KIERLAND BALLROOM 2

GENERAL SESSIONS

KIERLAND BALLROOM 3

EXHIBIT HALL HOURS

THURSDAY, MAY 9

7:00 AM - 7:30 AM 9:30 AM - 10:00 AM 3:45 PM - 4:15 PM

NETWORKING RECEPTION 5:30 PM - 6:30 PM

FRIDAY, MAY 10

7:00 AM - 7:30 AM 9:30 AM - 10:00 AM 3:00 PM - 3:30 PM

ABBVIE

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedIn.

1 N. Waukegan Road North Chicago, Illinois 60064 (248)830-1274

3542 East Rawhide Street JONATHAN.KELLY@ABBVIE.COM

AMERICAN TMS CLINICS

American TMS clinics is a leader in modern mental health solutions, utilizing Personalized Transcranial Magnetic Stimulation to ne-tune our patients brain activity, leading to decreased symptoms of depression, anxiety, PTSD, OCD, autism, and more! American TMS Clinics are dedicated to providing customized treatment plans tailored to each individual patient's needs. Alongside advanced TMS services, American TMS Clinics also o er comprehensive medication management to ensure a holistic approach to mental health care, supporting patients through every step of their treatment journey.

1474 N Northsight Blvd B-111, #453 Scottsdale, Arizona 85260 (480)482-9091 http://americantmsclinics.com brian@americantmsclinics.com

BRAINWEEK

1801 N Military Trail Ste 100

Boca Raton, Florida 33431 (561)997-0112

C2N DIAGNOSTICS

C₂N Diagnostics, LLC provides clinical laboratory services and advanced diagnostic solutions in the eld of brain health. Our high-resolution, mass spectrometry-based blood biomarker products are used for: clinical decision-making, including diagnosis and treatment monitoring; maximizing the quality and e ciency of clinical trials; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease. C₂N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world.

4340 Duncan Avenue St. Louis, Missouri 63110 (877)226-3424 www.precivityad.com info@c2n.com

EISAI

At Eisai, everything we do is guided by a simple principle: patients and their families come rst. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. We call this human health care or hhc, giving rst thoughts to patients and their families and helping increase the bene ts health care provides.

200 Metro Blvd. Nutley, New Jersey 07110 (201)692-1100 http://us.eisai.com info@eisai.com

EXHIBITOR DIRECTORY

HARMONY BIOSCIENCES

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases. Our team of experts from a wide variety of disciplines and experiences are driven by our shared conviction that innovative science translates into therapeutic possibilities for patients, who are at the heart of everything we do.

630 W. Germantown Pike Suite 215 Plymouth Meeting, Pennsylvania 19462 (267)221-5350 www.wakixhcp.com medinfo@harmonybiosciences.com

LUNDBECK

6 Parkway North Deer eld, Illinois 60015

(866)337-6996

www.lundbeck.com/us

USA@lundbeck.com www.lundbeck.com/us

MEDEIA

OXYHEALTH

OxyHealth has forever changed the way the medical industry practices hyperbaric therapy. Since our inception, we are devoted to providing quality and brilliantly safe portable hyperbaric chambers to physicians, professional athletes, wellness centers, and families. All OxyHealth chambers are designed for patients to easily self-treat, which has fostered a cutting-edge trend in hyperbaric technology.

10719 Norwalk Blvd

Santa Fe Springs, California 90670 (562)619-2515 www.oxyhealth.com events@oxyhealth.com www.facebook.com/oxyhealthllc www.instagram.com/oxyhealth

PFIZER

Since its inception in 1992, Medeia Inc has been on the forefront in the manufacture and distribution of Neuro Diagnostic and Heart Rate Variability / ANS products. Medeia Inc specializes in the development of state of the art biometrical so ware and hardware products intended to monitor physiology for research and educational purposes.

7 W. Figueroa St., Ste.215 Santa Barbara, California 93101

+18004334609

www.medeia.com info@medeia.com

At P zer, we apply science and our global resources to bring therapies to people that extend and signi cantly improve their lives. To learn more, please visit us at www.P zer.com

66 Hudson Blvd East New York, New York 10001 (800)879-3477 www.p zer.com

RLS

Our advanced technology uses targeted wavelengths of infra-red light to penetrate deep into the body, promoting cellular rejuvenation and enhancing the body’s natural healing processes. This natural and non-invasive approach to pain relief and wellness has been shown to improve circulation, reduce in ammation, and alleviate pain and discomfort.

2602 Harlered Drive Glendale, Arizona 85304 (209)936-5301 http://rlsolution.com info@therlsolution.com

SCILEX HOLDING COMPANY

SCILEX Holding Company is committed to the development and commercialization of nonopioid pain management products. Scilex has launched ELYXYBTM (celecoxib oral solution), the only FDA-approved ready-to-use nonsteroidal anti-in ammatory oral solution for the acute treatment of migraine, with or without aura, in adults. The company also promotes ZTlido® (lidocaine topical system) 1.8%, a revolutionary lidocaine patch FDA-approved for the treatment of neuropathic pain of post-herpetic neuralgia (PHN).

960 San Antonio Road

Palo Alto, California 94303 (732)927-3146

www.scilexholding.com mmacchia@scilexholding.com

WAVI MEDICAL

WAVi Medical provides objective measurements that inform both the doctor and the patient as to brain function. The FDA Cleared device utilizes EEG and evoked potential measurements as well as neurocognitive and symptom assessments to give a 360 view of the brain. Our patented, easy to use headset allows for any sta person to conduct the test with a short 2 hour training while ensuring the patient does not have a "bad hair day". Come by for a demo.

3857 Steele St. Suite 1293

Denver, Colorado 80205 (713)823-1945 www.WAVimed.com info@wavimed.com